In another in vitro mouse model, sensitization of tumor cells with bortezomib led to lysis that was mediated by enhanced DR5 and Fas expression accompanied with downregulation of MHC class I. The authors could show in a murine tumor model that bortezomib-treatment in bone marrow transplantation together with NK cell immunotherapy increased survival (Hallett et al., 2008). This evidence concerns the gene FAS and neoplasm.